Endocannabinoids

Click2Contact

BIOMOL International offers a comprehensive listing of products in the field of Endocannabinoid research. The company also manufactures other molecular tools which modulate levels of Endocannabinoids or block their uptake.

The company offers antibodies to the receptors, antagonists, stable non-metabolisable agonists and a stock library containing 60 different Endocannabinoids.

Over the past few years several discoveries have been made, stimulating intense research in Endocannabinoids. These include the discovery of two Cannabinoids receptors termed the CB1 and CB2 receptors and, very recently, a third receptor which most likely will be classified as a CB3 receptor.

It is believed that drugs aimed at CB1 and CB2 receptors may represent new therapeutics for a wide range of diseases such as inflammatory diseases, obesity, glaucoma, neurodegenerative diseases, nausea, multiple sclerosis, movement disorders and cardiovascular diseases. Analgesia is another important unmet medical need for which the Endocannabinoid system may provide new drugs.